12.26.15

Gemini version available ♊︎

Insensitivity at the EPO’s Management – Part II: Patent Office as a Cancer

Posted in Europe, Patents at 5:47 am by Dr. Roy Schestowitz

Cancer letter

Summary: The EPO’s stance on cancer recalled, in light of an altercation from 2013 (patent application no. EP03017743.0, appeal number T0598/12-3.3.02)

THE management of the EPO has resorted to what we consider both unethical and potentially illegal tactics. Union busting has taken such a high priority that every trick out of the book has been harnessed, with help from external (contracted) firms.

During Christmas we were contacted by a person who is able to show us just how jaw-dropping the EPO’s management can be with regards (or disregard) to cancer. As a preparatory item, consider the following letter, which is nearly a couple of years old (emphasis with large fonts is ours):

Brussels, March 12th, 2014

M. Benoît Battistelli
President – European Patent Office
Erhardtstr. 27
80469 Munich
Germany

Dear M. Battistelli,

My name is Francesco De Lorenzo and I am the President of the European Cancer Patient Coalition – ECPC, which represents 345 cancer patient organizations in 47 countries.

ECPC regularly engages with its members, EU institutions and international health and cancer care stakeholders to protect and enhance cancer patients’ rights in Europe, making sure that the voice of European citizens, affected by cancer, is heard.

That is why we are addressing you to express our concerns regarding the recent decision from the European Patent Office (EPO), Patent application no. EP03017743.0, appeal number T0598/12-3.3.02 on whether a clinical trial invalidates the request for a new drug patent.

“That is why we are addressing you to express our concerns regarding the recent decision from the European Patent Office (EPO), Patent application no. EP03017743.0, appeal number T0598/12-3.3.02 on whether a clinical trial invalidates the request for a new drug patent.”We believe that EPO’s position on the matter should take in due consideration the effects it will have on the future treatment of cancer patients and their ability to dispose of new and innovative drugs. We are concerned, in fact, that EPO’s current interpretation of the matter may make clinical trials more difficult to carry out and hence undermine critical innovation in medicine.

Clinical trials are research studies conducted on patients to evaluate the safety and efficacy of medicines intended to improve their health and provide the necessary scientific data and information to develop new medicines. ECPC believes that patent policy should encourage innovation, particularly innovation arising from clinical trials. A clinical trial cannot and should not be construed as a patent defeating disclosure. Should this happen, there will eventually be serious implications for the development of life-saving medicines.

“We are concerned, in fact, that EPO’s current interpretation of the matter may make clinical trials more difficult to carry out and hence undermine critical innovation in medicine.”Patients are not only a fundamental partner in the development of new drugs, but they are also those who will finally benefit from the innovation process. In particular, we strongly believe that it is natural that a patient may discuss his/her participation or clinical experience with their physician and family members. It is clear that patients participating in clinical trials should not be considered as members of the public, but rather key collaborators and important and voluntary participants of the trial. However, given their particular situation and knowledge level, patients cannot be compared either to other clinical trials actors, such as researchers. Hence patients cannot share the same confidentiality responsibility as researchers: this would, in fact, represent an unfair burden over the patients’ shoulders, which does not match patients’ level of biomedical and scientific understanding of clinical trials nor the reason for which they participate in them.

“ECPC believes that patent policy should encourage innovation, particularly innovation arising from clinical trials. A clinical trial cannot and should not be construed as a patent defeating disclosure.”Aside from the pure legal perspective, it is to be expected that EPO decision on the 2013 case mentioned before, if implemented, will lead to reduced transparency and/or delay of implementation of new clinical trials, which are both to the detriment of patients’ interests. Reducing transparency will threaten the access to investigational drugs that clinical trials provide for patients. This access is of critical importance for cancer patients, particularly for those whose only treatment option may be a clinical trial.

Alternatively, delaying clinical trials until patent applications are filed, will add undue delay to the very time consuming process of developing a new medicine that could improve patients’ lives. Such patent policy also excludes any innovation that arises during a clinical trial.

“Aside from the pure legal perspective, it is to be expected that EPO decision on the 2013 case mentioned before, if implemented, will lead to reduced transparency and/or delay of implementation of new clinical trials, which are both to the detriment of patients’ interests.”In conclusion, we strongly believe that the invention or findings related to a clinical trial should not be considered as “made available to the public” only because patients participate actively to the aforementioned trial. The patients’ unique status, in between collaborators and beneficiaries, makes them a key and vulnerable stakeholder, whose necessities are to be protected. Therefore, we would be glad to engage with EPO and all other relevant stakeholders in order to re-discuss the legal status and responsibilities of patients enrolled in clinical trials.

ECPC also believes that research should be encouraged and that public policy should remove barriers to the conduct of clinical trials, while keeping very high security standards and ensuring ethical conduct.

We hope that you will re-examine the decision in question for the benefit of patients. We remain at your disposal to further discuss the issue.

Sincerely,

Prof. F. De Lorenzo

To see how this relates to the series as a whole stay tuned for future parts. It is clear that patent scope has gone awry at the EPO, for the sake of protectionism, greed, and profit. Remember this when the EPO make claims on “productivity” (however misleading these claims can be) and ponder what this really translates into.

Share in other sites/networks: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Reddit
  • email

Decor ᶃ Gemini Space

Below is a Web proxy. We recommend getting a Gemini client/browser.

Black/white/grey bullet button This post is also available in Gemini over at this address (requires a Gemini client/browser to open).

Decor ✐ Cross-references

Black/white/grey bullet button Pages that cross-reference this one, if any exist, are listed below or will be listed below over time.

Decor ▢ Respond and Discuss

Black/white/grey bullet button If you liked this post, consider subscribing to the RSS feed or join us now at the IRC channels.

DecorWhat Else is New


  1. Links 28/05/2023: eGates System Collapses, More High TCO Stories (Microsoft Windows)

    Links for the day



  2. IRC Proceedings: Saturday, May 27, 2023

    IRC logs for Saturday, May 27, 2023



  3. No More Twitter, Mastodon, and Diaspora for Tux Machines (Goodbye to Social Control Media)

    People would benefit from mass abandonment of such pseudo-social pseudo-media.



  4. Links 28/05/2023: New Wine and More

    Links for the day



  5. Links 27/05/2023: Plans Made for GNU's 40th Anniversary

    Links for the day



  6. Social Control Media Needs to be Purged and We Need to Convince Others to Quit It Too (to Protect Ourselves as Individuals and as a Society)

    With the Tux Machines anniversary (19 years) just days away we seriously consider abandoning all social control media accounts of that site, including Mastodon and Diaspora; social control networks do far more harm than good and they’ve gotten a lot worse over time



  7. Anonymously Travelling: Still Feasible?

    The short story is that in the UK it's still possible to travel anonymously by bus, tram, and train (even with shades, hat and mask/s on), but how long for? Or how much longer have we got before this too gets banned under the false guise of "protecting us" (or "smart"/"modern")?



  8. With EUIPO in Focus, and Even an EU Kangaroo Tribunal, EPO Corruption (and Cross-Pollination With This EU Agency) Becomes a Major Liability/Risk to the EU

    With the UPC days away (an illegal and unconstitutional kangaroo court system, tied to the European Union in spite of critical deficiencies) it’s curious to see EPO scandals of corruption spilling over to the European Union already



  9. European Patent Office (EPO) Management Not Supported by the EPO's Applicants, So Why Is It Still There?

    This third translation in the batch is an article similar to the prior one, but the text is a bit different (“Patente ohne Wert”)



  10. EPO Applicants Complain That Patent Quality Sank and EPO Management Isn't Listening (Nor Caring)

    SUEPO has just released 3 translations of new articles in German (here is the first of the batch); the following is the second of the three (“Kritik am Europäischen Patentamt – Patente ohne Wert?”)



  11. German Media About Industry Patent Quality Charter (IPQC) and the European Patent Office (EPO)

    SUEPO has just released 3 translations of new articles in German; this is the first of the three (“Industrie kritisiert Europäisches Patentamt”)



  12. Geminispace Continues to Grow Even If (or When) Stéphane Bortzmeyer Stops Measuring Its Growth

    A Gemini crawler called Lupa (Free/libre software) has been used for years by Stéphane Bortzmeyer to study Gemini and report on how the community was evolving, especially from a technical perspective; but his own instance of Lupa has produced no up-to-date results for several weeks



  13. Links 27/05/2023: Goodbyes to Tina Turner

    Links for the day



  14. HMRC: You Can Click and Type to Report Crime, But No Feedback or Reference Number Given

    The crimes of Sirius ‘Open Source’ were reported 7 days ago to HMRC (equivalent to the IRS in the US, more or less); but there has been no visible progress and no tracking reference is given to identify the report



  15. IRC Proceedings: Friday, May 26, 2023

    IRC logs for Friday, May 26, 2023



  16. One Week After Sirius Open Source Was Reported to HM Revenue and Customs (HMRC) for Tax Fraud: No Response, No Action, Nothing...

    One week ago we reported tax abuses of Sirius ‘Open Source’ to HMRC; we still wait for any actual signs that HMRC is doing anything at all about the matter (Sirius has British government clients, so maybe they’d rather not look into that, in which case HMRC might be reported to the Ombudsman for malpractice)



  17. Links 26/05/2023: Weston 12.0 Highlights and US Debt Limit Panic

    Links for the day



  18. Gemini Links 26/05/2023: New People in Gemini

    Links for the day



  19. IRC Proceedings: Thursday, May 25, 2023

    IRC logs for Thursday, May 25, 2023



  20. Links 26/05/2023: Qt 6.5.1 and Subsystems in GNUnet

    Links for the day



  21. Links 25/05/2023: Mesa 23.1.1 and Debian Reunion

    Links for the day



  22. Links 25/05/2023: IBM as Leading Wayland Pusher

    Links for the day



  23. IRC Proceedings: Wednesday, May 24, 2023

    IRC logs for Wednesday, May 24, 2023



  24. Links 25/05/2023: Istio 1.16.5 and Curl 8.1.1

    Links for the day



  25. Gemini Links 25/05/2023: On Profit and Desire for Gemini

    Links for the day



  26. SiliconANGLE: Sponsored by Microsoft and Red Hat to Conduct the Marriage Ceremony

    SiliconANGLE insists that paying SiliconANGLE money for coverage does not lead to bias, but every sane person who keeps abreast of SiliconANGLE — and I read their entire feed every day — knows that it’s a ludicrous lie (Red Hat/IBM and the Linux Foundation also buy puff pieces and “event coverage” from SiliconANGLE, so it’s marketing disguised as “journalism”



  27. Links 24/05/2023: Podman Desktop 1.0, BSDCan 2024, and More

    Links for the day



  28. Gemini Links 24/05/2023: Razors, Profit, and More

    Links for the day



  29. [Meme] When the Patent Office Controls Kangaroo Patent Courts and Judges

    The EPO has been hijacked by industry and its lobbyists; now the same is happening to EU patent courts, even though it is illegal and unconstitutional



  30. The Illegally 'Revised' Unified Patent Court Agreement (UPCA) is Disgracing the Perception of Law and Order in the European Union

    The Unified Patent Court (UPC) isn’t legal, the Unified Patent Court Agreement (UPCA) is being altered on the fly (by a person patently ineligible to do so), and so it generally looks like even patent courts across Europe might soon become as corrupt as the European Patent Office, which has no basis in the Rule of the Law and is basically just a front for large corporations (most of them aren’t even European)


RSS 64x64RSS Feed: subscribe to the RSS feed for regular updates

Home iconSite Wiki: You can improve this site by helping the extension of the site's content

Home iconSite Home: Background about the site and some key features in the front page

Chat iconIRC Channel: Come and chat with us in real time

Recent Posts